Last reviewed · How we verify

NCT04694820

A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia

Completed NA Last updated 29 April 2025
What this trial tests

NA trial testing Text Message-Based Navigation Intervention in Chronic Myelogenous Leukemia, BCR-ABL1 Positive in 30 participants. Completed in 8 April 2022.

Timeline
5 June 2020
Primary endpoint
8 April 2022
8 April 2022

Quick facts

Lead sponsorThomas Jefferson University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposesupportive care
Enrollment30
Start date5 June 2020
Primary completion8 April 2022
Estimated completion8 April 2022
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Thomas Jefferson University

Who can join

18 and older, any sex, with Chronic Myelogenous Leukemia, BCR-ABL1 Positive or Chronic Phase Chronic Myelogenous Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial studies the feasibility and acceptability of a mobile intervention called txt4TKI for the improvement of tyrosine kinase inhibitor management in patients with chronic myeloid leukemia. Tyrosine kinase inhibitors (TKI) are associated with numerous potential side effects, including a decrease in bone marrow activity (myelosuppression), nausea, diarrhea, fatigue, and soft-tissue swelling (edema), especially in the face and lower legs, which are the primary reasons for patients to discontinue TKI medication. Using a mobile text messaging (TXT) intervention that emphasizes the importance of TKI compliance may improve TKI adherence in patients with chronic myeloid leukemia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Text Message-Based Navigation Intervention

Trials testing the same drug.

Other recruiting trials for Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Currently open trials in the same condition.

Other Thomas Jefferson University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04694820.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing